| Literature DB >> 26563749 |
Carolina Scagnolari1, Katia Monteleone2, Carla Selvaggi3, Alessandra Pierangeli4, Gabriella D'Ettorre5, Ivano Mezzaroma6, Ombretta Turriziani7, Massimo Gentile8, Vincenzo Vullo9, Guido Antonelli1.
Abstract
Given the multifactorial nature of action of type I interferon (IFN) in HIV-1 infection and the need to firmly establish the action of key components of IFN pathways, we compared the IFN stimulated gene (ISG)15 expression with that of other well-characterized ISGs, evaluating its relationship with immunosuppressive factors regulating T-cell response in HIV-1 patients. PBMC from 225 subjects were included: healthy donors (n=30), naïve (n=93) and HAART treated HIV-1 subjects (n=102). Levels of ISG15-mRNA, ISG56-mRNA, APOBEC3G/3F-mRNA, TRAIL-mRNA, IDO-mRNA, proviral load andISG15 (rs15842 and rs1921) SNPs were evaluated by using TaqMan assays. We found that ISG15, ISG56, APOBEC3G/3F levels were increased in untreated HIV-1 patients compared to healthy donors, being ISG15 the highest ISG expressed. The amount of ISG15 correlated with viral load and with CD4+ T cell counts whereas no relationship was found between all ISGs analyzed and proviral load or HIV-1 tropism. ISG15 expression was reduced following long-term antiretroviral therapy. In addition, ISG15 levels were correlated with those of TRAIL and IDO in HIV-1 viremic patients. Lastly, ISG15 SNPs had no influence on ISG15 levels. We demonstrates that ISG15 is elevated in viremic HIV-1 patients and is associated with high TRAIL and IDO levels.Entities:
Keywords: APOBEC3F; APOBEC3G; HIV-1; IDO; IFN; ISG15; TRAIL
Mesh:
Substances:
Year: 2015 PMID: 26563749 DOI: 10.1016/j.imbio.2015.10.007
Source DB: PubMed Journal: Immunobiology ISSN: 0171-2985 Impact factor: 3.144